We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A European Parliament committee is proposing that the European Commission promote transparency in private research to foster better access to medicines across the EU. Read More
For years, Mylan has dodged paying the appropriate rebates for its epinephrine auto-injector EpiPen through a misclassification, the Centers for Medicare and Medicaid Services confirmed. Read More
The FDA intends to clarify its expectations for demonstrating the interchangeability of biosimilars with reference products, an FDA official said. Read More
Over 90 percent of clinical trials evaluating targeted cancer therapies or immunotherapies fell short in reporting adverse events in their publications — specifically in reporting recurrent or late toxicities, and detailing the duration of adverse events — according to researchers who studied 81 trials related to FDA-approved solid tumor treatments. Read More
Novartis will pay more than $35 million to settle off-label promotion charges when the company marketed its eczema cream, Elidel, for use on infants. Read More